Orme and his research team in Fort Collins investigated whether the existing
vaccine for
TB, which goes by the acronym BCG (bacille Calmette - Guerin), worked equally well against different clinical
strains of tuberculosis.
«With more than 1.7 million people dying globally from
TB each year and the rise of
strains that are resistant to drug treatment, we need a better way to prevent this disease,» said the study's principal investigator Louis Picker, M.D., who is the associate director of the OHSU
Vaccine and Gene Therapy Institute and a professor of pathology, molecular microbiology, and immunology in the OHSU School of Medicine.